2019/07/22

The INDICATE project (IN vitro DIagnostic CAncer Test) promises to revolutionize diagnostic systems for lung cancer.

 IndicateWeb

The INDICATE project (IN vitro DIagnostic CAncer Test) promises to revolutionize diagnostic systems for lung cancer. Thanks to the device currently being developed by researchers at Biodonostia, Ceit-IK4, CIC biomaGUNE and DIPC, users will be able to know quickly and in a private setting whether they have lung cancer, a pathology with one of the highest annual death rates around the world (1.76 million in 2018). In fact, last year Spain recorded more than 23,000 deaths from lung cancer, the vast majority of which—82%—were men.

Led by Biodonostia’s head of oncology, Charles Lawrie, also an Ikerbasque research professor and CEO of Indicate Solutions (a spin-off created to commercialize this technology), this project feeds into to the development of this self-diagnostic platform, which is in an advanced stage of development and expected to arrive on the market in the near future. Dr. Lawrie is joined by researchers Sergio Arana, principal investigator at Ceit-IK4, Marek Grzelczak, principal investigator at DIPC, and Luis Liz-Marzan, scientific director of CIC biomaGUNE.

The multidisciplinary team is making progress on the initial phase of developing the prototype, which will revolutionize the diagnostic sector with its fast and reliable performance. In fact, thanks to this project, it will be possible to receive a cancer diagnosis and check on treatment on the same day that the test is administered, without having to wait a month as is currently the case. In this way, treatment of the diagnosed cancer can begin immediately and how the disease reacts to treatment can be monitored, making it possible to adjust the treatment as soon as it stops being effective.

Thanks to the funding obtained from the Basque Government and the Carlos III Health Institute, the project has demonstrated the validity of the core technology behind the device and has assembled it in a laboratory prototype. Currently, the developers are seeking both private and public funding in order to exploit the idea and carry out the next phase, which consists of developing a device for the market.

RELATED INFORMATION